Incretin-based Therapy in Chronic Kidney Disease

被引：8
作者：
Pinelli, Nicole R. [1 ]
Moore, Carol L.
Tomasello, Sarah
机构：
[1] Wayne State Univ, Eugene Applebaum Coll Pharm & Hlth Sci, Dept Pharm Practice, Detroit, MI 48201 USA
来源：
ADVANCES IN CHRONIC KIDNEY DISEASE | 2010年 / 17卷 / 05期
关键词：
Diabetes mellitus; Chronic kidney disease; End stage renal disease; Incretins; Glucagon like peptide-1; DIPEPTIDYL PEPTIDASE-4 INHIBITOR; GLUCAGON-LIKE PEPTIDE-1; IMPROVES GLYCEMIC CONTROL; DOUBLE-BLIND; METFORMIN THERAPY; RENAL IMPAIRMENT; HEALTHY-SUBJECTS; GLP-1; ANALOG; SITAGLIPTIN; SAFETY;
D O I：
10.1053/j.ackd.2010.06.003
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
Type 2 diabetes mellitus (T2DM) with concomitant CKD is an emerging clinical and public health problem reaching epidemic proportions in the United States. Achieving and maintaining glycemic targets in clinical practice are significant challenges in majority of the patients with T2DM and CKD, and this has created significant barriers for clinicians managing these patients. Commonly used antihyperglycemic agents are either contraindicated or lack efficacy and safety information in this population. Recently, 2 distinct classes of agents that augment incretin hormone action have been added to the therapeutic armamentarium targeting hyperglycemia. This review will discuss the literature examining the efficacy and safety of incretin-based therapies in T2DM and the available evidence for their use in CKD. (C) 2010 by the National Kidney Foundation, Inc. All rights reserved.
引用
收藏
页码：439 / 449
页数：11
相关论文
共 58 条
[1]  
*AM PHARM INC, 2005, BYETT EX PRESCR INF
[2]   Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes [J].
Aschner, Pablo ;
Kipnes, Mark S. ;
Lunceford, Jared K. ;
Sanchez, Matilde ;
Mickel, Carolyn ;
Williams-Herman, Debora E. .
DIABETES CARE, 2006, 29 (12) :2632-2637
[3]  
*ASTRAZENECA PHARM, 2009, ONGL SAX PRESCR INF
[4]   Effect of renal insufficiency on the pharmacokinetics of sitagliptin, a dipeptidyl peptidase-4 inhibitor [J].
Bergman, Arthur J. ;
Cote, Josee ;
Yi, Bingming ;
Marbury, Thomas ;
Swan, Suzanne K. ;
Smith, William ;
Gottesdiener, Keith ;
Wagner, John ;
Herman, Gary A. .
DIABETES CARE, 2007, 30 (07) :1862-1864
[5]   Effect of Sitagliptin on the Pharmacokinetics of Simvastatin [J].
Bergman, Arthur J. ;
Cote, Josee ;
Maes, Andrea ;
Zhao, Jamie J. ;
Roadcap, Brad A. ;
Sun, Li ;
Valesky, Robert J. ;
Yang, Amy ;
Keymeulen, Bart ;
Mathijs, Zissi ;
De Smet, Marina ;
Laethem, Tine ;
Davies, Michael J. ;
Wagner, John A. ;
Herman, Gary A. .
JOURNAL OF CLINICAL PHARMACOLOGY, 2009, 49 (04) :483-488
[6]  
Bjornsdottir I, 2008, DIABETOLOGIA, V51, pS356
[7]   Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6) [J].
Buse, John B. ;
Rosenstock, Julio ;
Sesti, Giorgio ;
Schmidt, Wolfgang E. ;
Montanya, Eduard ;
Brett, Jason H. ;
Zychma, Marcin ;
Blonde, Lawrence .
LANCET, 2009, 374 (9683) :39-47
[8]   Saxagliptin added to a submaximal dose of sulphonylurea improves glycaemic control compared with uptitration of sulphonylurea in patients with type 2 diabetes: a randomised controlled trial [J].
Chacra, A. R. ;
Tan, G. H. ;
Apanovitch, A. ;
Ravichandran, S. ;
List, J. ;
Chen, R. .
INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2009, 63 (09) :1395-1406
[9]   Safety and efficacy of sitagliptin in patients with type 2 diabetes and chronic renal insufficiency [J].
Chan, J. C. N. ;
Scott, R. ;
Ferreira, J. C. Arjona ;
Sheng, D. ;
Gonzalez, E. ;
Davies, M. J. ;
Stein, P. P. ;
Kaufman, K. D. ;
Amatruda, J. M. ;
Williams-Herman, D. .
DIABETES OBESITY & METABOLISM, 2008, 10 (07) :545-555
[10]   Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone [J].
Charbonnel, Bernard ;
Karasik, Avraham ;
Liu, Ji ;
Wu, Mei ;
Meininger, Gary .
DIABETES CARE, 2006, 29 (12) :2638-2643
123456